+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Alpha 1 Antitrypsin Deficiency Treatment: Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • September 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5309866

Quick Summary:

In the continuously expanding healthcare sector, the global market for Alpha 1 Antitrypsin Deficiency Treatment is projected to burgeon to an impressive size of US$3.8 Billion by 2030, making it a significant investment opportunity. This marked increase, from an estimated US$1.9 Billion in 2022, underlines the rapid development and adoption of various treatment options, including Augmentation Therapy and Bronchodilator treatments.

Possessing a foothold in this market space positions you competitively amidst pandemic recovery. Further, it allows you to leverage growth and expansion opportunities across different geographic borders. Having an acute understanding of the market, U.S, China, Japan, Canada, and Europe are seeing rapid progress, opening avenues for investments and collaborations. This report delineates the global competitiveness, potential market shares and presences across multiple geographies. With bespoke professional updates, online peer-to-peer collaborative assessments, you also gain access to digital archives and the publisher's Research Platform, with complimentary updates for a year, ensuring you stay on the top of the game.

Global Alpha 1 Antitrypsin Deficiency Treatment Market to Reach $3.8 Billion by 2030

The global market for Alpha 1 Antitrypsin Deficiency Treatment estimated at US$1.9 Billion in the year 2022, is projected to reach a revised size of US$3.8 Billion by 2030, growing at a CAGR of 9% over the analysis period 2022-2030. Augmentation Therapy, one of the segments analyzed in the report, is projected to record 9.7% CAGR and reach US$1.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Bronchodilator segment is readjusted to a revised 9.5% CAGR for the next 8-year period.

The U.S. Market is Estimated at $575.4 Million, While China is Forecast to Grow at 8.2% CAGR

The Alpha 1 Antitrypsin Deficiency Treatment market in the U.S. is estimated at US$575.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$635 Million by the year 2030 trailing a CAGR of 8.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.2% CAGR.

Select Competitors (Total 46 Featured) -

  • Abeona Therapeutics Inc.
  • Applied Genetic Technologies Corporation
  • Arrowhead Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • CSL Behring
  • Curaxys
  • GlaxoSmithKline PLC
  • Grifols International SA
  • Kamada Ltd.
  • Pfizer, Inc.
  • ProBioGen AG
  • ProMetic Life Sciences, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and the publisher's Research Platform
  • Complimentary updates for one year

Frequently Asked Questions about the Global Market for Alpha 1 Antitrypsin Deficiency Treatment

What is the estimated value of the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?

The Global Market for Alpha 1 Antitrypsin Deficiency Treatment was estimated to be valued at $1.9 Billion in 2022.

What is the growth rate of the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?

The growth rate of the Global Market for Alpha 1 Antitrypsin Deficiency Treatment is 9.1%, with an estimated value of $3.8 Billion by 2030.

What is the forecasted size of the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?

The Global Market for Alpha 1 Antitrypsin Deficiency Treatment is estimated to be worth $3.8 Billion by 2030.

Who are the key companies in the Global Market for Alpha 1 Antitrypsin Deficiency Treatment?

Key companies in the Global Market for Alpha 1 Antitrypsin Deficiency Treatment include Abeona Therapeutics Inc., Applied Genetic Technologies Corporation, Arrowhead Pharmaceuticals Inc., AstraZeneca PLC, Baxter International, Inc., Biogen, Inc., Boehringer Ingelheim International GmbH, Chiesi Farmaceutici SpA, CSL Behring and Curaxys.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Alpha 1 Antitrypsin Deficiency Treatment - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Alpha 1 Antitrypsin Deficiency Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Augmentation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Augmentation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Bronchodilator by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Bronchodilator by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Oxygen Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Oxygen Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 18: World 16-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Specialty Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 21: World 16-Year Perspective for Specialty Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 24: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 27: World 16-Year Perspective for Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 28: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 29: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 30: World 16-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 31: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 32: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 33: World 16-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 34: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 35: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 36: World 16-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
  • Table 37: World Alpha 1 Antitrypsin Deficiency Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • CANADA
  • JAPAN
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • CHINA
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • EUROPE
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • FRANCE
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • GERMANY
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • ITALY
  • UNITED KINGDOM
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • REST OF EUROPE
  • ASIA-PACIFIC
  • Alpha 1 Antitrypsin Deficiency Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • REST OF WORLD
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abeona Therapeutics Inc.
  • Applied Genetic Technologies Corporation
  • Arrowhead Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Baxter International, Inc.
  • Biogen, Inc.
  • Boehringer Ingelheim International GmbH
  • Chiesi Farmaceutici SpA
  • CSL Behring
  • Curaxys
  • GlaxoSmithKline PLC
  • Grifols International SA
  • Kamada Ltd.
  • Pfizer, Inc.
  • ProBioGen AG
  • ProMetic Life Sciences, Inc.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.